In 2020, as part of the fight against COVID-19, we have witnessed incredible collaborations between biotech, big pharma, academia and not-for-profit organizations, all working together to develop treatments and vaccines at record speed. Global demand for products treating and preventing infection with the virus presents huge opportunities for the biomanufacturing sector, along with challenges in managing limited global bioreactor capacity, maximizing manufacturing efficiencies, and adopting facilities to work with new and innovative technologies.
Vaccines, monoclonal antibodies, cytokines and other ‘biopharmaceuticals’ all make use of biomanufactured products. Their creation involves the use of scalable, validated biotech processes that use biological organisms, or parts of biological organisms, to produce useful products, naturally or through advanced genetic engineering techniques. The first bio pharma products approved for therapeutic use was biosynthetic human insulin made via recombinant DNA. It was developed by Genentech, but licensed to Eli Lilly & Co, who manufactured and marketed it in 1982, under the trade name Humulin. Dominated by small biotechs, R&D investment in new medicines by the biopharma industry stood at $102 billion in 2018, and the sector had been predicted to grow at a rate of around 10% per year over the next four to five years.
That was before COVID.
About 75% of COVID-19 treatments – at various stages of development – are produced in mammalian cell culture. Even if only a fraction of these products reach the market, a significant proportion of people requiring treatment for the symptoms of COVID are going to be using products manufactured in this way. In itself, this might not seem to be a challenge – after all, in 2019, the top 10 biopharma products were produced in mammalian cell culture. The biopharma market has long been dominated by monoclonal antibodies, so the equipment exists to deliver on those demands. However, as explained by Patti Seymour (Managing Director, BDO USA) in a recent webinar hosted by CPhI, in order to treat 25 million patients (the number of people believed to have contracted the virus so far), about 150 x 10,000L bioreactors would be required. This represents the entire world’s current capacity for mammalian systems. Therefore, in a worst-case scenario, if existing bioreactors were given over to the production of COVID-19 treatments, there would be limited capacity for others, including those needed for some types of cancer. In other words, with the world’s current capacity for biomanufacturing, demand for COVID-19 treatments has the potential to severely disrupt the production of other important medicines.
This situation presents tremendous opportunities for urgent investment in increased bioreactor capacity. Current estimates suggest that only about 20% of biomanufacturing capacity is provided by CMOs. With demand looking fairly certain to exceed current capacity, this would appear to be an obvious area for good return on investment.
Decisions surrounding new investments in capacity for biomanufacturing should consider the impact of continuous bioprocessing, which is becoming more mainstream technology. As pointed out by Eric Langer (President and Managing Partner, BioPlan Associates), biomanufacturing productivity and efficiency have never been more important, and continuous bioprocessing is providing an increasingly common answer to these challenges. In particular, the industry has been looking at continuous perfusion, purification/chromatography, bioprocess control and monitoring. CMOs are often on the cutting edge of these innovative technologies, and are in a prime position to provide high-value, competitive services.
The COVID-19 pandemic has also been a driving factor in changing the way that the industry produces vaccines. Traditional approaches, using eggs or blood plasma to grow the virus and develop antigens, are simply not quick enough. On ...
(All Rights Reserved)